Company news
Fortress Biotech, Inc. news in 2024
Fortress Biotech, Inc.'s news releases, calls and decks from 2024, newest first.
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
December 12, 2024
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 13, 2024
Fortress Biotech to Participate in October 2024 Investor Conferences
September 25, 2024
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
September 19, 2024
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
September 15, 2024
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 3, 2024
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 12, 2024
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
July 24, 2024
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
July 4, 2024
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
May 13, 2024
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
April 28, 2024
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
March 27, 2024
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
March 3, 2024
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 2, 2024